Product Access

Choosing an authorized specialty distributor



Besse Medical

Phone: 1-800-543-2111 1-800-543-2111

Fax: 1-800-543-8695 1-800-543-8695

Web Orders:

Cardinal Health Specialty


Phone: 1-877-599-7748 1-877-599-7748

Fax: 1-800-862-6208 1-800-862-6208

Web Orders:

McKesson MPB

Phone: 1-877-625-2566 1-877-625-2566

Fax: 1-888-752-7626 1-888-752-7626

Web Orders:

McKesson Specialty Care Distribution

Phone: 1-855-477-9800 1-855-477-9800

Fax: 1-800-800-5673 1-800-800-5673

Web Orders:

Metro Medical
(A Cardinal Health Company)

Phone: 1-800-768-2002 1-800-768-2002

Fax: 1-615-256-4194 1-615-256-4194

Web Orders:

Novartis does not recommend the use of any particular distributor.

Specialty pharmacy providers

BEOVU is also available to any specialty pharmacy.

Product returns

If you have questions regarding how to return BEOVU, please contact Novartis Pharmaceuticals Corporation (NPC) by phone 1-800-526-0175 1-800-526-0175 or e-mail at

Billing and coding resources

The information herein is provided for educational purposes only. Novartis cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

Patient support

Eligible commercially insured patients must be enrolled in co-pay support via BEOVU GO™ prior to December 17, 2021. You will be able to submit co-pay claims for dates of service on or before December 31, 2021. All claims will need to be submitted by March 31, 2022. Any claims submitted after that point will not be paid.

To submit a claim, download the forms and submission instructions or call 1-888-612-3688
Monday – Friday, 8:00 AM to 8:00 PM ET.


BEOVU® (brolucizumab-dbll) injection is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).




BEOVU is contraindicated in patients with ocular or periocular infections, active intraocular inflammation or known hypersensitivity to brolucizumab or any of the excipients in BEOVU. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.


Endophthalmitis and Retinal Detachment

Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachment. Proper aseptic injection techniques must always be used when administering BEOVU. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Retinal Vasculitis and/or Retinal Vascular Occlusion

Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of BEOVU. Patients should be instructed to report any change in vision without delay.

Increase in Intraocular Pressure

Acute increases in intraocular pressure (IOP) have been seen within 30 minutes of intravitreal injection including with BEOVU. Sustained IOP increases have also been reported. Both IOP and perfusion of the optic nerve head must be monitored and managed appropriately.

Thromboembolic Events

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the BEOVU clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The ATE rate in the two controlled 96-week neovascular AMD studies (HAWK and HARRIER) during the first 96-weeks was 4.5% (33 of 730) in the pooled brolucizumab arms compared with 4.7% (34 of 729) in the pooled aflibercept arms.


Serious adverse reactions including endophthalmitis, retinal detachment, retinal vasculitis and/or retinal vascular occlusion, increases in intraocular pressure, and arterial thromboembolic events have occurred following intravitreal injections with BEOVU.

The most common adverse events (≥5% of patients) with BEOVU were vision blurred, cataract, conjunctival hemorrhage, vitreous floaters and eye pain.

As with all therapeutic proteins, there is a potential for an immune response in patients treated with BEOVU. Anti-brolucizumab antibodies were detected in the pre-treatment sample of 36% to 52% of treatment naive patients. After initiation of dosing, anti-brolucizumab antibodies were detected in at least one serum sample in 53% to 67% of patients treated with BEOVU. Intraocular inflammation was observed in 6% of patients with anti-brolucizumab antibodies detected during dosing with BEOVU. The significance of anti-brolucizumab antibodies on the clinical effectiveness and safety of BEOVU is not known.


BEOVU® (brolucizumab-dbll) injection is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).

Please see the Important Safety Information and full Prescribing Information for BEOVU.